EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study

Wei-Chen Lin iD, Wei-Chen Tai, Chung-Hsin Chang, Chia-Hung Tu, I-Che Feng, Ming-Jium Shieh, Chen-Shuan Chung, Hsu-Heng Yen, Jen-Wei Chou, Jau-Min Wong, Yu-Hwa Liu, Tien-Yu Huang und 27 weitere

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izac269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Wei-Chen Lin und 38 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease, Hepatitis B. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceuticals Taiwan, Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This nationwide prospective registry study investigated the real-world effectiveness, safety, and persistence of vedolizumab (VDZ) in inflammatory bowel disease (IBD) patients in Taiwan. Disease relapse rates after VDZ discontinuation due to reimbursement restriction were assessed.

Methods

Data were collected prospectively (January 2018 to May 2020) from the Taiwan Society of IBD registry.

Results

Overall, 274 patients (147 ulcerative colitis [UC] patients, 127 Crohn’s disease [CD] patients) were included. Among them, 70.7% with UC and 50.4% with CD were biologic-naïve. At 1 year, 76.0%, 58.0%, 35.0%, and 62.2% of UC patients and 57.1%, 71.4%, 33.3%, and 30.0% of CD patients achieved clinical response, clinical remission, steroid-free remission, and mucosal healing, respectively. All patients underwent hepatitis B and tuberculosis screening before initiating biologics, and prophylaxis was recommended when necessary. One hepatitis B carrier, without antiviral prophylaxis due to economic barriers, had hepatitis B reactivation during steroid tapering and increasing azathioprine dosage, which was controlled with an antiviral agent. No tuberculosis reactivation was noted. At 12 months, non–reimbursement-related treatment persistence rates were 94.0% and 82.5% in UC and CD patients, respectively. Moreover, 75.3% of IBD patients discontinued VDZ due to mandatory drug holiday. Relapse rates after VDZ discontinuation at 6 and 12 months were 36.7% and 64.3% in CD patients and 42.9% and 52.4% in UC patients, respectively.

Conclusions

The findings demonstrated VDZ effectiveness in IBD patients in Taiwan, with high treatment persistence rates and favorable safety profiles. A substantial IBD relapse rate was observed in patients who had mandatory drug holiday.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesColitis, UlcerativeCrohn DiseaseHepatitis BHumansTaiwanRemission InductionGastrointestinal AgentsRecurrenceTreatment OutcomeRetrospective StudiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Crohn’s diseasereimbursementulcerative colitisvedolizumab

Substanzen

Gastrointestinal AgentsvedolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Wei-Chen Lin, Shu-Chen Wei

Förderung

  • Takeda Pharmaceuticals Taiwan, Ltd.

Zitieren

APA

Lin, W. C., Tai, W. C., Chang, C. H., Tu, C. H., Feng, I. C., Shieh, M. J., Chung, C. S., Yen, H. H., Chou, J. W., Wong, J. M., Liu, Y. H., Huang, T. Y., Chuang, C. H., Tsai, T. J., Chiang, F. F., Lu, C. Y., Hsu, W. H., Yu, F. J., Chao, T. H., …, & Wei, S. C. (2023). Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac269

Vancouver

Lin WC, Tai WC, Chang CH, Tu CH, Feng IC, Shieh MJ, et al. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac269

BibTeX
@article{Lin2023,
  author = {Lin, Wei-Chen and Tai, Wei-Chen and Chang, Chung-Hsin and Tu, Chia-Hung and Feng, I-Che and Shieh, Ming-Jium and Chung, Chen-Shuan and Yen, Hsu-Heng and Chou, Jen-Wei and Wong, Jau-Min and Liu, Yu-Hwa and Huang, Tien-Yu and Chuang, Chiao-Hsiung and Tsai, Tzung-Jiun and Chiang, Feng-Fan and Lu, Chien-Yu and Hsu, Wen-Hung and Yu, Fang-Jung and Chao, Te-Hsin and Wu, Deng-Chyang and Ho, Ai-Sheng and Lin, Hung-Hsin and Feng, Chun-Lung and Wu, Keng-Liang and Wong, Ming-Wun and Tung, Chien-Chih and Lin, Chun-Chi and Chen, Chia-Chang and Hu, Huang-Ming and Lu, Lung-Sheng and Wang, Huann-Sheng and Wu, I-Chen and Kuo, Hsin-Yu and Wu, Jia-Feng and Yao Shih, Hsiang and Ni, Yen-Hsuan and Tang, Shu-Lun and Chen, Peng-Hsu and Wei, Shu-Chen},
  title = {Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izac269}
}
Kostenlos starten →